WO2023105057A1

WO2023105057A1 - 2-(2,5-dimethoxyphenyl)ethanamine for use in the treatment and/or prevention of skin diseases

Info

Publication number: WO2023105057A1
Application number: PCT/EP2022/085214
Authority: WO
Inventors: Fredrik Von Kieseritzky; Gabriella SMEDFORS; Ulf Bremberg
Original assignee: Amidea Sweden Ab
Priority date: 2021-12-10
Filing date: 2022-12-09
Publication date: 2023-06-15
Also published as: SE2151519A1

Abstract

The disclosure provides a compound of Formula (I) for use as a medicament. The disclosure also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Further, the disclosure provides a compound of Formula (I), or a pharmaceutical composition comprising said compound of Formula (I), for use in the treatment and/or prevention of a skin disorder such as an inflammatory skin disorder.

Description

2-(2,5-DIMETHOXYPHENYL)ETHANAMINE AND USES THEREOF Technical field The present disclosure relates to the compound 2-(2,5-dimethoxyphenyl)ethanamine and uses thereof. More specifically, the present disclosure relates to 2-(2,5- dimethoxyphenyl)ethanamine for use in the treatment of a skin disorder such as an inflammatory skin disorder. Background Skin inflammation disorders affect people of all ages and in all countries. In the field of dermatology, inflammatory disease is the most common ailment. While some inflammatory skin disorders may be easily resolved others are more challenging to treat. Rosacea, perioral dermatitis and atopic dermatitis are all skin inflammatory disorders which are difficult or impossible to cure, and treatment only involves relief of symptoms and/or the symptoms return after the treatment. Moreover, the treatment often has insufficient effects, is associated with negative side effects and/or takes place during a long time such as from months up to several years. For example, there is no cure for rosacea and known treatments merely provide relief of symptoms. In a further example, atopic dermatitis is frequently treated with corticosteroids which is accompanied by substantial negative side effects such as thinning of the skin and possible rebound phenomena, i.e. worsening of symptoms after treatment cessation. In still a further example, perioral dermatitis often returns after completion of the treatment. Rosacea is a relatively common dermatosis occurring in about 2–10% of all adults with its main location in the center of the face. It affects adults with the distribution women: men in a ratio of 3: 1 and is more common in skin types 1-2 according to the Fitzpatrick scale, i.e. people generally having a fair skin. No clear heredity for rosacea is known and the underlying cause is unknown. The dominant hypothesis is that rosacea is both an inflammatory and vascular disease, the proportions varying between different patients. There is no evidence of bacterial genesis. Rosacea is characterised by episodes of flush. This is triggered primarily by sun radiation but often also by alcohol, strong spices or other vasodilating stimuli. Rosacea may be associated with flushing and constant redness, small dilated blood vessels and papules on the cheeks, nose and possibly forehead. Swelling and burning sensation is also possible in the center of the face. The rosacea disease also includes an increased number of pronounced telangiectasias In a small number of patients, there is hyperplasia of tissue, i.e. an enlargement of tissue, especially the nose resulting in rhinophyma. Eye irritations are common in rosacea, in the form of various non- characteristic eye inflammations. Perioral dermatitis is an inflammatory condition involving a red rash around e.g. the mouth or nose. It can cause scaly, dry and flaky skin with papules. Stinging or burning sensation is not rare. It can also be periorbital as well as perinasal, which is why the term periorificial dermatitis (POD) may be preferred. POD can affect all age categories and ethnicities, but women aged 20-45 are overrepresented. The cause of perioral dermatitis is unknown. The development of symptoms is often subacute and take from weeks to month(s). Further, episodes of POD can last weeks to months. Symptoms can look like those associated with acne and POD is often mistaken for acne. POD can also be misinterpreted as eczema and local steroid treatment can initially have a soothing effect, only to significantly worsen the symptoms later on during or after completed treatment or upon discontinuation of the treatment. Further treatment options include metronidazole, azelaic acid, adapalene, topical or oral antibiotics, sulfur preparations, immunomodulatory creams such as ivermectin or tacrolimus. It has been observed that POD may return after the treatment. Patients suffering from atopic dermatitis such as atopic eczema have itching and generally dry skin (xerosis) with poor barrier function. The atopic patient often describes an acute reddening of the skin just before the eczema worsens. The cause of this rash may be food or some other antigen, for which the patient is sensitized. IgE-mediated histamine release triggers an itching cycle. The atopic eczema often worsens acutely. The itching leads to tearing with excoriation and secondary infection. The skin damage and infection associated with atopic dermatitis provokes increasing cytokine release from keratinocytes with an increasingly pronounced eczema as a result. Psychedelics are a class of hallucinogenic drugs whose primary effect is to trigger non-ordinary states of consciousness (known as psychedelic experiences or "trips") via serotonin 2A receptor agonism. This causes specific psychological, visual and auditory changes, and often a substantially altered state of consciousness. However, there is now emerging evidence that some psychedelic substances may also provide anti-inflammatory effects and research has been conducted to explore these substances. For example, phenethylamines have been studied as described below. Phenethylamines is a class of psychedelic drugs which are known to bind to serotonin 5-HT2A receptors, which modulate the activity of key circuits in the brain involved with sensory perception and cognition. A sub class of phenethylamines are the so-called 2C or 2C-x psychedelics, which have methoxy substituents in the 2 and 5 positions of a phenyl ring. These compounds generally have a lipophilic substituent in the 4 position of the phenyl ring, which has been found to make them more potent, metabolically stable and long acting. In contrast, the so-called 2C-H compound lacks a substituent in the 4 position of the phenyl ring. The 2C-H compound, which may also be denominated 2-(2,5- dimethoxyphenyl)ethanamine, has been found to be metabolically unstable which is believed to be due to its destruction by monoamine oxidase enzymes. This is likely to explain why there are no records of 2C-H trials in humans and no registration of 2C-H as an Active Pharmaceutical Ingredient. WO 2020/210823 A1 discloses compounds and methods for treating inflammatory disorders. It is disclosed that 2C compounds can provide anti-inflammatory efficacy without eliciting behavioral effects mediated by action in the central nervous system (CNS). It is described that the 2C compounds may be compounds in which R is CH2CH(CH3)2 (formula I), CH2C(CH3)3 (formula II), or CH2CH(CH2)2 (formula III). The compound 2C-H is not disclosed. WO 2020/181194 A1 discloses compositions and methods of use of 5-HT2A agonists administered as modulators of neural plasticity, at non-psychedelic/psychomimetic dosages, posology and formulations, for treatment of diseases and conditions for improving functions. An aspect of the disclosure is a structural analogue to 2,5- dimethoxy-4-iodoamphetamine. It is mentioned that the compounds may be used in the treatment of NS inflammation including inflammation from autoimmune disorders. The compound 2C-H is not disclosed. ACS Pharmacol. Transl. Sci, 2021, 4, pp.488-502 relates to structure-activity relationship analysis of psychedelics in a rat model of asthma. It is described that the drug 2C-H represents the pharmacophore for anti-inflammatory activity, and structural modifications that are either permissive or detrimental to anti-inflammatory activity are identified. WO 2007/044752 A2 relates to methods and materials involved in treating skin disorders. The document provides methods and materials for treating skin disorders using an alpha adrenergic receptor agonist (e.g. midodrine). The compound 2C-H is not mentioned.

J. Med. Chem. 1981, 24, pp. 1432-1437 discloses a series of phenethylamines related to methoxamine prepared and evaluated for direct al-receptor agonist activity. It is described that phenethylamines with unrestricted conformations, such as compound 13, are less potent as direct al agonists than those with well-defined orientations such as compound 5.

There is a need for further pharmaceutical drugs for use in the treatment and/or prevention of skin disorders such as inflammatory skin disorders. In particular, there is a need for pharmaceutical drugs for use in the treatment and/or prevention of rosacea, perioral dermatitis and/or atopic dermatitis.

Summary

It is an object of the present disclosure to overcome or at least mitigate some of the problems associated with the treatment of skin disorders such as inflammatory skin disorders. Further, it is an object of the present disclosure to provide aspects and/or advantages not provided by hitherto known technique.

The present disclosure provides a compound of Formula I:

or a pharmaceutically acceptable salt thereof, for use as a medicament.

Further, the present disclosure provides a pharmaceutical composition comprising a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent.

The present disclosure also provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition as described herein for use in the treatment and/or prevention of a skin disorder such as an inflammatory skin disorder. The present disclosure also provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition as described herein for use in the manufacture of a medicament for the treatment and/or prevention of a skin disorder such as an inflammatory skin disorder. The present disclosure also provides a method for treatment and/or prevention of a skin disorder such as an inflammatory skin disorder, said method comprising administering to a mammal, such as a human or an animal, in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition as described herein. Brief description of the drawings Figure 1 shows the clinical signs of the treatment groups G1-G5 described herein. Figure 2 shows a graph of combined ear thicknesses for the treatment groups G1-G5 described herein. Figure 3 shows a graph of combined ear weight for the treatment groups G1-G5 described herein. Figure 4A shows the histopathology score with respect to acanthosis for the treatment groups G1-G5 described herein. Figure 4B shows the histopathology score with respect to dermal infiltration for the treatment groups G1-G5 described herein. Figure 4C shows the histopathology score with respect to subcorneal microabscess for the treatment groups G1-G5 described herein. Figure 4D shows the cumulative histopathology score for the treatment groups G1-G5 described herein. Figure 5 shows the reduction of IL-1 α for different concentrations of added 2C-H. Figure 6 shows the reduction of IL-1βfor different concentrations of added 2C-H. Figure 7 shows the reduction of IL-6for different concentrations of added 2C-H. Figure 8 shows the reduction of IL 10for different concentrations of added 2C-H. Figure 9 shows the reduction of IL-18 for different concentrations of added 2C-H.

Figure 10 shows the reduction of TNF-α for different concentrations of added 2C-H.

Description

The present disclosure provides a compound of Formula I:

or a pharmaceutically acceptable salt thereof, for use as a medicament.

It will be appreciated that the compound of Formula I may be denominated 2C-H. Further, the chemical name of the compound of Formula I may be 2-(2,5- dimethoxyphenyljethanamine, 2-(2,5-dimethoxyphenyl)ethan-l-amine or 2,5- dimethoxy-phenethylamine.In this document, the terms compound of Formula I, compound 2C-H, and 2-(2,5-dimethoxyphenyl)ethanamine are used interchangeably.

The present disclosure is based on the unexpected finding that the compound of Formula I may be used as a medicament. In contrast to other so-called 2C or 2C-x psychedelic drugs the compound of Formula I is known to be metabolically unstable and has therefore not been of interest for use as a pharmaceutical drug. However, the present inventors have found that the compound of Formula I may in fact be used as a pharmaceutical drug. In particular, it has been found that the compound of Formula I, or a pharmaceutical composition thereof as described herein, allows for treating and/or preventing a skin disorder, such as an inflammatory skin disorder, such as rosacea, perioral dermatitis and/or atopic dermatitis. Advantageously, it has also been found that the compound of Formula I, or a pharmaceutical composition thereof as described herein, is free from negative side effects such as hallucinogenic effects or other effects associated with psychedelic drugs.

As used herein, the term "skin disorder" is understood to mean a skin abnormality and/or a skin condition causing discomfort.

Further, the present disclosure provides a pharmaceutical composition comprising a compound of Formula I as described herein, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent. It will be appreciated that the pharmaceutical composition may be configured for a specific use. For example, the pharmaceutical composition may be configured depending on e.g. the site of the body and/or the type of skin disorder that is to be treated. For example, the pharmaceutical composition may be a topical pharmaceutical composition such as a topical pharmaceutical composition intended to deliver the compound of Formula I to the skin, such as a site of the skin involving an inflammatory skin disorder. Additionally or alternatively, the topical pharmaceutical composition may be an ophtalmological pharmaceutical composition intended to deliver the compound of Formula I to the eye. It will be appreciated that the pharmaceutical composition described herein may be free from MAOIs, i.e.monoamineoxidase inhibitors. The pharmaceutical composition described herein may be provided as one or more of the following: solution, emulsion, aerosol, spray, foam, lotion, cream, ointment, gel, paste, eye drops, eye ointment. In an example, there is provided a topical skin composition which is provided as one or more of the following: solution, emulsion, aerosol, spray, foam, lotion, cream, ointment, gel, paste. In a further example, the pharmaceutical composition is an ophtalmological pharmaceutical composition comprising or consisting of eye drops or eye ointment. The pharmaceutical composition may be provided as an article comprising or consisting of said pharmaceutical composition. Thus, there is provided an article comprising the pharmaceutical composition described herein. The article may be a disposable article or an article that may be reused. Further, the article may be partly or entirely biodegradable thereby reducing the environmental impact of said article. Moreover, the article may be sized and configured to fit into a user´s pocket, handbag and/or common storage places in e.g. a bathroom or kitchen. The article may be selected from the group consisting of: a dispenser optionally provided with an applicator, a pad, a wipe, a patch. For instance, the article may be selected from the group consisting of a bottle or can provided with actuating means, a spray can, a wet wipe and a dermal patch. Additionally or alternatively, the article may be one or more of the following: a pad, A wipe such as a pad, a wipe such as a wet wipe, a patch such as a dermal patch. Thus, there is provided a pad, a wipe such as a wet wipe and/or a patch such as a dermal patch comprising the pharmaceutical composition described herein. In particular, the article may be a bottle or can provided with actuating means such as pump dispenser. For example, the pump dispenser may be refillable and/or allow for metering a specific amount of the pharmaceutical composition enclosed in the dispenser. In further example, the dispenser may be a tube such as a tube having substantially the same size as a regular tube for toothpaste. In still a further example the dispenser may be a spray can. The spray can may optionally be pressurized and/or allow for dispensing the pharmaceutical composition as aerosol(s) and/or foam(s). In yet a further example, the dispenser may be provided with a permeable material such as a membrane allowing for dispensing the pharmaceutical composition upon e.g. actuation and/or application of pressure. Alternatively, the dispenser may be provided with a so-called roll-on-ball of the kind used in the context of deodorants allowing for supplying the pharmaceutical composition by means of the roll-on-ball. Further, the article may be a bottle or can without actuating means. For example, the article may be a bottle or can comprising the pharmaceutical composition in the form of a stick that may be applied to a treatment site. Moreover, the article may be a wipe such as a wet wipe, i.e. a substantially moist wipe which may include the pharmaceutical composition. Advantageously, there is provided a wrapped bag containing one or more wet wipes with an opening means which may be re-closable such a re-closable lid. The wet wipe(s) may contain an amount of the pharmaceutical composition that is suitable for treating a specific skin disorder as described herein. Further, the article described herein may be provided as a patch such as a dermal patch. The dermal patch may contain an adhesive allowing it to adhere to a treatment site, such as a site affected by a skin disorder as described herein, to deliver the pharmaceutical composition to and into the skin. In contrast to a transdermal patch, a dermal patch will deliver the pharmaceutical composition to and into the treatment site without or substantially without delivering the pharmaceutical composition into the bloodstream. Thus, in this way the risk for undesired side effects is minimized. Further, the metabolic instability of the compound of Formula I also reduces the risk for undesired side effects. The present disclosure also provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition as described herein for use in the treatment and/or prevention of a skin disorder such as an inflammatory skin disorder. The present disclosure also provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition as described herein for use in the manufacture of a medicament for the treatment and/or prevention of a skin disorder such as an inflammatory skin disorder. The present disclosure also provides a method for treatment and/or prevention of a skin disorder such as an inflammatory skin disorder, said method comprising administering to a mammal, such as a human or an animal, in need thereof an effective amount, such as a therapeutically effective amount, of a compound of Formula I, or a pharmaceutically acceptable salt thereof, as described herein, or a pharmaceutical composition as described herein. The treatment described herein may be symptomatic treatment, i.e. treatment of one or more symptoms such as symptom(s)associated with the skin disorder, and/or curative treatment. The skin disorder described herein may involve inflammation, i.e. it may be an inflammatory skin disorder. The skin disorder such as the inflammatory skin disorder may or may not include psoriasis. For instance, the skin disorder such as the inflammatory skin disorder may be one or more of the following: rosacea, perioral dermatitis, atopic dermatitis. It will be appreciated that the skin disorder described herein may be chronic, non-chronic and/or recurring. The rosacea described herein may be one or more of the following four subtypes of rosacea: erythematotelangiectactic rosacea, papulopustular rosacea, phymateous rosacea, ocular rosacea. Further, the rosacea may be erythematotelangiectactic rosacea and/or papulopustular rosacea. The rosacea described herein may involve reddish skin, with papules and/or pustules on the face such as on or near the cheeks, the eyes, the nose and/or the mouth. Erythematotelangiectactic rosacea is understood to be a vascular form of rosacea involving dilated blood vessels and persistent redness around the face. Papulopustular rosacea is an inflammatory form of rosacea, which may appear similar to acne, involving papules and pustules around the face. Phymateous rosacea involves growth of excess tissue causing thickening of the skin and modularity around the nose, cheeks, lips, eyes and/or tears. Ocular rosacea involves the skin around the eyes which becomes red and thickened, and/or may also involve the eyes and/or eye lids causing redness, watering of the eye, itching and/or blurred vision. The rosacea described herein may take place in mammals such as humans being from 20 years to 75 years old such as around 45 years old. In particular, the rosacea may take place in women and/or people with fair skin. Further, the skin disorder may comprise or consist of perioral dermatitis. The perioral dermatitis described herein, which may also be denominated periorificial dermatitis, may comprise or consist of inflammatory rash involving the skin around the mouth and/or nose. When the perioral dermatitis takes place around the mouth it may be called periorbital dermatitis. When the perioral dermatitis takes place around the nose it may be called perinasal dermatitis. Further, the skin disorder may comprise or consist of atopic dermatitis. The atopic dermatitis described herein, which may also be called atopic eczema, may comprise or consist of itchy, red, swollen and/or cracked skin. It will be appreciated that the compound of Formula I or the pharmaceutical composition may be administered to a desired site for treatment such as skin involving inflammation or eye conjunctiva. The amount of the compound of Formula I or the pharmaceutical composition administered to the treatment site may be adjusted to achieve a desired therapeutic effect such as curing and/or relief of symptoms, i.e. the amount may be a therapeutically effective amount. For instance, the compound of Formula I or the pharmaceutical composition may be administered to a treatment site surface to provide the compound of Formula I in a dosage from about 0.01 mg/cm² to about 10 mg/cm². Further suitable dosages include dosages from about 0.1 mg/ cm² to about 10 g/cm², such as from about 5 mg/ cm² to about 20 mg/ cm², such as from about 10 mg/ cm² to about 100 mg/cm², such as from about 1 g/ cm² to about 10 g/ cm². Moreover, the compound of Formula I or pharmaceutical composition described herein may be administered to the treatment site an appropriate number of times with a frequency suitable to achieve the desired therapeutic effect. For instance, the compound of Formula I or the pharmaceutical composition may be administered daily such as once daily. Moreover, the compound of Formula I or pharmaceutical composition described herein may be administered during a suitable period of time such as a time sufficient to remove the symptoms associated with the skin disorder. It will be appreciated that the compound of Formula I described herein may be provided as a pharmaceutically acceptable salt such as an acid addition salt. For example, the pharmaceutically acceptable salt may be a combination of the compound of Formula I and an acid such as a combination of the compound of Formula I and the acid in a ratio of 1:1 or 2:1. In particular, the pharmaceutically acceptable salt of the compound of Formula I may be a combination of the compound of the compound of Formula I with HCl taken in a ratio of 1:1. Other pharmaceutically acceptable salts of the compound of Formula I include acetate, benzoate, bensylate, citrate, fumarate, gluconate, hydrobromide, isethionate, lauryl sulfate (estolate), malate, mesylate, napsylate, napsylate, oleate, pamoate, phosphate, succinate, sulfate and tartrate salt(s). It will be appreciated that the pharmaceutically acceptable salt(s) of the compound of Formula I may be co-crystallized with e.g. water. It will be appreciated that the compound of Formula I described herein may be provided as a solvate or as a solvent of a pharmaceutically acceptable salt of the compound of Formula I. Further aspects

The present disclosure also provides the following further aspects.

Further aspect 1 :

A compound of Formula I:

or a pharmaceutically acceptable salt thereof, for use as a medicament.

Further aspect 2:

A pharmaceutical composition comprising a compound of Formula I as defined in further aspect 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent.

Further aspect 3:

The pharmaceutical composition according to further aspect 3, which is free from monoamine oxidase inhibitors.

Further aspect 4:

The pharmaceutical composition according to further aspect 2 or 3, wherein said pharmaceutical composition is a topical pharmaceutical composition.

Further aspect 5:

The pharmaceutical composition according to any one of further aspects 2-4, wherein the pharmaceutical composition is provided as a solution, emulsion, aerosol, spray, foam, lotion, cream, ointment, gel, paste or eye drops.

Further aspect 6:

The pharmaceutical composition according to any one of further aspects 2-5, which is provided as an article comprising said pharmaceutical composition.

Further aspect 7:

The pharmaceutical composition according to further aspect 6, wherein the article is selected from the group consisting of: a dispenser optionally provided with an applicator, a pad, a wipe, a patch. Further aspect 8: The pharmaceutical composition according to further aspect 6 or 7, wherein the article is selected from the group consisting of a bottle or can provided with actuating means, a spray can, a wet wipe and a dermal patch. Further aspect 9: A compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in further aspect 1, or a pharmaceutical composition according to any one of further aspects 2-8 for use in the treatment and/or prevention of a skin disorder. Further aspect 10: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to further aspect 9, or the pharmaceutical composition for use according to further aspect 9, wherein the skin disorder is an inflammatory skin disorder. Further aspect 11: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to further aspect 9 or 10, or the pharmaceutical composition for use according to further aspect 9 or 10, wherein the skin disorder does not comprise psoriasis. Further aspect 12: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of further aspects 9-11, or the pharmaceutical composition for use according to any one of further aspects 9-11, wherein the skin disorder is one or more of the following: rosacea, perioral dermatitis, atopic dermatitis. Further aspect 13: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to further aspect 12 or the pharmaceutical composition for use according to further aspect 12, wherein the skin disorder is rosacea. Further aspect 14: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to further aspect 12 or 13, or the pharmaceutical composition for use according to further aspect 12 or 13, wherein the rosacea is one or more of the following types of rosacea: erythematotelangiectactic rosacea, papulopustular rosacea, phymateous rosacea, ocular rosacea. Further aspect 15: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of further aspects 12-14, or the pharmaceutical composition for use according to any one of further aspects 12- 14, wherein the rosacea is erythematotelangiectactic rosacea and/or papulopustular rosacea. Further aspect 16: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of further aspects 9-12, or the pharmaceutical composition for use according to any one of further aspects 9-12, wherein the skin disorder is atopic dermatitis. Further aspect 17: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of further aspects 9-12, or the pharmaceutical composition for use according to any one of further aspects 9-12, wherein the skin disorder is perioral dermatitis. Further aspect 18: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of further aspects 9-17, or the pharmaceutical composition for use according to any one of further aspects 9-17, wherein the compound of Formula I or the pharmaceutical composition is administered to provide the compound of Formula I in a dosage from 0.01 mg/cm² to 10 mg/cm². Further aspect 19: The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of further aspects 9-18, or the pharmaceutical composition for use according to any one of further aspects 9-18, wherein the pharmaceutical composition is administered daily such as once daily The disclosure will be further described by reference to the following examples, which are not intended to limit the scope of the disclosure.

Examples Abbreviations API Active Pharmaceutical Ingredient CAS Chemical Abstracts Service CMC carboxymethyl cellulose cm² square centimeter such as square centimeter of surface of treatment site DMSO dimethyl sulfoxide GM-CF granulocyte-macrophage colony–stimulating factor H&E hematoxylin and eosin staining HP Hunched Posture hr(s) hour(s) IL interleukin nm nanometer(s) MDM human monocyte differentiated macrophages mg milligram(s) mL milliliter(s) mm millimeter(s) NAD No Abnormality Detected, NBF Neutral Buffered Formalin OD optical density OXA oxazolone as described herein Oxa oxazolone as described herein P ptosis PBMC peripheral blood mononuclear cell RPMI Roswell Park Memorial Institute TNF-D Tumor Necrosis factor-D UKC Unkempt coat w/v weight by volume ~ about In this document, unless otherwise stated, the naming and the drawing of the chemical compounds have been made using the program ChemDraw Ultra 12.0.2.1076. In the event that there is a discrepancy between nomenclature and any compounds depicted graphically, then it is the latter that presides (unless contradicted by any experimental details that may be given or unless it is clear from the context). General 2-(2,5-Dimethoxyphenyl)ethanamine hydrochloride (2C-H x HCl) was synthesized according to British Journal of Pharmacology (2007) 152, 1121–1130 (DOI: 10.1038/sj.bjp.0707473). Example 1a: Preparation of Composition 1a 2-(2,5-Dimethoxyphenyl)ethanamine hydrochloride (i.e. 2C-H x HCl) 100 mg was dissolved in 1 mL of a commercially available composition containing of denatured ethanol containing phospholipids extracted from soybeans. The commercially available composition was AKVANO® Skin Disinfection from the company Lipidor, Sweden, purchased in a pharmacy in Stockholm, Sweden. After stirring at room temperature, a clear solution with an API concentration of the 2-(2,5-dimethoxyphenyl)ethanamine of 10 mg/mL was obtained. This pharmaceutical composition was denominated Composition 1a and transferred to sealed vials and used as such. Example 1b: Preparation of Composition 1b 2-(2,5-Dimethoxyphenyl)ethanamine hydrochloride (i.e. 2C-H x HCl) 25 mg was dissolved in 2.5 mL water and further diluted with a commercially available composition containing of Aloe barbadensis leaf juice, glycerin, polyacrylate crosspolymer-6, phenoxyethanol, ethylhexylglycerin, panthenol, propylene glycol and tert-butyl alcohol. The commercially available composition was CCS® Aloe Vera Gel from the company CCS Skincare Brands AB, purchased in a pharmacy in Stockholm, Sweden. After thoroughly mixing at room temperature, a clear gel with an API concentration of the 2-(2,5-dimethoxyphenyl)ethanamine of 10 mg/mL was obtained. This pharmaceutical composition was denominated Composition 1b and transferred to sealed vials and used as such. Example 2a: Treatment of rosacea The study object was a 35-year-old Caucasian male who had been suffering from treatment resistant chronic rosacea for about 15 years. The study object had previously tried several treatment regimens, (e.g. Metronidazole, Ivermectin, azelaic acid, CBD- oil) without noteworthy effect, and as for azelaic acid with side effects in the form of dryness. 0.1 mL of Composition 1a as prepared in Example 1a was administered topically once daily to the affected skin areas of the study object. Within 24 h after the first administration a noticeable decrease of redness occurred. Over the following days redness kept decreasing, papules diminished swelling decreased and the feeling of being sore was diminished. The study object was followed for 28 days and during this time no sustained adverse reactions were noted. However, a rapid increase of transitory redness on the treated skin appeared after application. This redness subsided for ~60 min whereafter the positive effects described above occurred. The acute redness effect of was judged to be a result of the high alcohol concentration in Composition 1a. No cognitive effects were observed. Thus, no hallucinatory or other psychedelic effects were observed. It was concluded that topical administration of the compound 2C-H, i.e. the compound of Formula I as described herein, had a therapeutic effect against rosacea. In particular, it was concluded that the symptoms associated with rosacea involving redness, papules, swelling and soreness decreased upon topical administration of the compound 2C-H. Further, it was concluded that the topical administration of the compound 2C-H did not provide any cognitive effects such as hallucinatory effects or other psychedelic effects. Example 2b: Treatment of rosacea The test person was the same 35-year-old Caucasian male suffering from treatment resistant chronic rosacea since ~15 years as in Example 2a. Since Composition 1a in Example 2a caused rapid albeit transitory irritation following administration, Composition 1b was prepared according to Example 1b. The study object thus terminated the treatment using Composition 1a and applied, once daily, 0.1 mL of Composition 1b on the affected skin areas. The results from Composition 1a were sustained during the treatment with Composition 1b, with a noticeable decrease of redness, papules, soreness and swelling. Application of Composition 1b caused an instant mild redness but no soreness. This redness subsided for ~30 min whereafter the positive effects described above occurred. The study object was followed for 14 days and during this time no adverse reactions were noted. No cognitive effects were observed. Thus, no hallucinatory or other psychedelic effects were observed. It was concluded that topical administration of the compound 2C-H provided as Composition 1b had a therapeutic effect against rosacea similar to that of Composition 1a. It was also concluded that rapid, transitory redness following administration of Composition 1a could be decreased by using the ethanol free Composition 1b. In particular, it was concluded that the symptoms associated with rosacea involving redness, papules, swelling and soreness were diminished upon topical administration of the compound 2C-H. Further, it was concluded that the topical administration of the compound 2C-H as prepared in Composition 1b did not provide any cognitive effects such as hallucinatory effects or other psychedelic effects. Example 3: Treatment of atopic dermatitis The study object was a Caucasian male in his early 20’s suffering from atopic dermatitis applied Composition 1a as prepared in Example 1 to the affected skin areas. 0.1-0.5 mL of Composition 1a was topically applied to the neck and wrists. His primary symptoms were itchy, dry, red and sensitive skin. The study object had previously been using hydrocortisone on the affected areas but had suffered side effects in the form of thinning skin and therefore this therapy was discontinued. Within fifteen minutes after the application of Composition 1a a noticeable decrease of itching was experienced. Within 2 hours after the application of Composition 1a redness and swelling decreased and kept decreasing for 24 hours. The effect was still noticeable after 36 h. No adverse events were noted. No cognitive effects were reported. It was concluded that topical administration of the compound 2C-H, i.e. the compound of Formula I as described herein, had a therapeutic effect against atopic dermatitis. In particular, it was concluded that the symptoms associated with atopic dermatitis involving itch, redness and swelling symptoms decreased upon topical administration of the compound 2C-H. Further, it was concluded that the topical administration of the compound 2C-H did not provide any cognitive effects such as hallucinatory effects or other psychedelic effects. Example 4: Evaluation of the treatment of atopic dermatitis using an atopic dermatitis disease model In this example the efficacy of topically applied test compound formulations in oxazolone induced chronic ear dermatitis in mice was studied. The compound 2C-H (i.e. the compound of Formula I described herein) was tested in two concentrations and compared to treatment groups G1-G3 as described below. Test system a) Species/Strain : BALB/c mice b) Sex : Female c) Age at the start of experiment : 8-10 weeks Test and control articles The test compound formulation 1 comprising the compound 2C-H was provided as a gel in a concentration of 1 w/v%. Details of the test compound formulation 1 and application thereof is provided in Table 1. As used herein, Kolliphor EL is polyethoxylated castor oil. Table 1: Test compound formulation 1:2C-H (1% w/v) gel Vehicle Propylene glycol (10%), Kolliphor EL (5%) Sodi m CMC (16%) Phos hate

gel in a concentration of 3 w/v%. Details of the test compound formulation 2 and application thereof is provided in Table 2. Table 2: Test compound formulation 2:2C-H (3% w/v) gel Vehicle Propylene glycol (10%), Kolliphor EL (5%) Sodi m CMC (16%) Phos hate

concentration of 0.1 % w/v. Details of the formulation and application thereof are shown in Table 3. As used herein, “D” stands for day. The number following “D” indicates the day for testing. Table 3: Formulation comprising betamethasone valerate (0.1% w/v cream) Manufacturer BETNOVATE (Glaxo Smith Kline Beecham)

The oxazolone with CAS number 15646-46-5 was used as sensitizing agent, i.e. as contact allergen. The oxazolone was purchased from Sigma Aldrich (product number E0753). As used herein, this oxazolone is denominated “oxazolone”. Treatment groups The mice were divided into five treatment groups G1-G5 as shown in Table 4.

Table 4

In Table 4, the term “n” denotes the number of mice. Study procedure a. Disease Induction, Monitoring and Tissue Sampling: x Animals were acclimatized for at least 7 days before initiation of the experiment. The animals reached at least 8-10 weeks of age before the sensitization was initiated. x Day -1: Animals were randomized into the above-mentioned groups such that the average body weight was uniform across the groups. x D0: Baseline ear thickness of all animals were measured using a Mitutoyo Quickmini micrometer. x D0: Animals were sensitized with the contact allergen, i.e. the oxazolone described herein, prepared as a 3% w/v solution in alcohol: acetone (4:1). 100 ǋ/ of the Oxazolone solution was topically applied to the previously depilated abdomen of the animals of the groups G2-G5. G1 animals received topical application of 100 ǋ/ of alcohol: acetone solution. x D5: Ear thickness of all animals was measured using a Mitutoyo Quickmini micrometer. x D5: Animals were challenged with the contact allergen prepared as a 2% w/v solution in alcohol: acetone (4:1). 20 ǋ/ of 2% w/v oxazolone in alcohol: acetone was applied topically (10 ǋ/^VLGH^ to both ears of animals of G2-G5. G1 animals received topical application of 20 ǋ/ of alcohol: acetone solution on both ears. x D6: Ear thickness 24 hrs post challenge was measured. x The animals were again challenged with the contact allergen on D10 and D14 and the ear thickness 24 hrs post challenge were measured on D10 and D15 respectively. x D15: Ear thickness 24 hr post challenge was measured. The animals were then bled under isoflurane anesthesia for serum collection. Post blood sampling the animals were sacrificed. Using a 6 mm biopsy punch a tissue sample was drawn from both ears and weighed. Left ear sample was stored in 10% NBF, processed, paraffin embedded, sectioned and slides were stained with H & E staining for histopathology. b. Treatment x The topical test formulations were applied for the various groups daily starting from the day of sensitization on D0. x G1 did not receive any treatment. G2 received the vehicle topical formulation topically (24 μL) once daily from D0-D14. G3 received 10 mg (10 μL) of 0.1% w/w Betamethasone cream from once daily D0 to D14. G4-G5 received 24 μL of the respective formulations applied onto the inner surface of the ear once daily from D0-D14. x When applied on the day of challenge i.e., D5, D10 and D14, the topical treatments were applied 6 hrs after oxazolone challenge to prevent the leaching of Oxazolone into the topically applied cream. x The test formulations for topical application were loaded into a 1 mL syringe and dispensed onto the inner surface of the ear. The ear was folded and gently massaged to ensure uniform dispersal across the inner surface. End points Ear thickness: In 40 animals on Day 0, Day 5, Day 6, Day 10, Day 11, Day 14 and Day 15. Ear weight: In 40 animals on Day 15. Histopathology (H&E): Qualitative evaluation of 40 Left ear samples (2 sections each from one animal on 1 slide). Histopathology grading criteria such as acanthosis, hyperkeratosis and microabscess formation will be provided with the results. Results The results are shown in Figures 1-3 and Figures 4A, 4B, 4C and 4D. Figure 1 shows that no adverse advents were observed for G4 in which the mice were treated with 2C-H (1% w/v) gel. Further, Figure 1 shows that only two adverse events occurred in G5 where the mice were treated with 2C-H (3% w/v) gel. In contrast, the mice in group G3 which were treated with betamethasone all experienced adverse advents during days 10-15. It was concluded that the treatment with 2C-H was associated with substantially no or no undesired side effects. Figure 2 shows a graph of combined ear thicknesses (i.e. thickness from both the left and right ears) for the groups G1-G5. From Figure 2 it can be observed that: - The combined ear thickness was significantly increased for oxazolone + vehicle (i.e. G2) on days 6, 10, 11, 14 and 15 when compared with the sham control group (i.e. G1). - The combined ear thickness was significantly decreased for the betamethasone group (G3) on days 5, 6, 10, 11, 14 and 15 when compared with the oxazolone + vehicle (G2). - The combined ear thickness was significantly decreased for the 2C-H (3%) gel (G5) when compared with the oxazolone + vehicle (i.e. G2). Further, it appears that the betamethasone reduced the ear thickness to a larger extent than 2C-H as shown e.g. by the bars for days D6, D10, D11, D14 and D15. Figure 3 shows a graph of combined ear weight for the groups G1-G5. From Figure 3 it can be observed that: - The combined ear weight (i.e. left and right ears combined) was significantly increased for oxazolone group (G2) when compared with the sham control group (G1). - The combined ear weight was significantly decreased for the betamethasone group (G3) when compared to the oxazolone group (G2). - The combined ear weight was significantly decreased for the 2C-H (3%) gel (G5) when compared to the oxazolone group (G2). Further, it appears that the betamethasone reduced the ear thickness to a larger extent than 2C-H. From Figures 2 and 3 it was concluded that 2C-H has an anti-inflammatory effect. Further, it was concluded that the anti-inflammatory effect of 2C-H is less than that of betamethasone. Thus, it appears that the anti-inflammatory effect is mild or moderate, such as mild or moderate anti-inflammatory effect as compared to the anti-inflammatory effect of betamethasone. Figures 4A-4D show the results of the histopathology assessment. Figure 4A shows the HP score (i.e. the histopathology score) with respect to acanthosis for the groups G1-G5. It was observed that was a significant decreased acanthosis score in OXA + betamethasone**** (G3) when compared with OXA + Vehicle group (G2). Figure 4B shows the HP score with respect to dermal infiltration for the groups G1- G5. It was observed that there was a significant decreased dermal infiltration score in OXA + betamethasone**** (G3), Oxa + 2C-H (1%) gel**(G4) and OXA + 2C-H (3%) gel**** (G5) when compared with OXA + Vehicle group (G1). It also appears that the 2C-H gels (G4 and G5, respectively) have less effect on the dermal infiltration as comparted to the betamethasone (G3). Figure 4C shows the HP score with respect to subcorneal microabscess for the groups G1-G5. It was observed that there was a significant decreased subcorneal microabscess score in OXA + betamethasone**** (G3) when compared with OXA + Vehicle group (G2). Figure 4D shows the cumulative HP score for the groups G1-G5. It was observed that there was a significant decreased cumulative score for the groups OXA + betamethasone**** (G3), Oxa + DP15 (1%)* (G4) and OXA + DP (3%)**(G5) when compared with OXA + Vehicle group (G2). Further, it was observed that the 2C-H gels (G4 and G5, respectively) decreased the cumulative HP score less than what was observed for betamethasone (G3). It was concluded that 2C-H has a mild or moderate anti-inflammatory effect and is associated with substantially no or no side effects. In contrast, betamethasone appears to have a higher anti-inflammatory effect compared to 2C-H but is associated with more side effects such as burning, itching, irritation, stinging, redness or dryness of the skin. The following p values are shown in the Figures: *p<0.05, *p<0.01, ***p<0.001, ****p<0.0001. Example 5: Assessment of cytokine release by human monocyte differentiated macrophages in response to treatment with 2C-H Overview x To assess the effect of test compound on the release of selected biomarkers from human monocyte differentiated macrophages (MDMs) x Assay type: ELISA x Targets assessed: IL-1ǃ, IL-10, IL-6, IL-18, TNF- Į, IL-1Į x Test compound: 2C-H x Treatment concentration, ǋM: 100, 10, 1, 0.1 x Positive control: MDM + 100ng/ml LPS + 0.1% DMSO x _{Negative control: MDM + 0.1% DMSO}

Table 5

1. Human PBMCs were isolated from human peripheral blood by Histopaque density gradient centrifugation. 2. Freshly isolated PBMCs were seeded at 2x10⁵ numbers/well in a 6-well plate and the monocytes were differentiated into macrophages by treatment with 200ng/mL of recombinant human GM-CSF (4mg/mL stock). 3. After 7 days of differentiation, MDMs were dosed with 2-CH at 100, 10, 1, 0.1 1μM final concentration. 4. Incubated for 1hrs at 37°C. 5. 100ng/mL of LPS (1mg/mL stock) was added to MDM’s 6. Incubated for 16 hrs at 37 °C. 7. Cells supernatant were used to assess cytokine activity by ELISA method as per manufacturers instructions. In this example, Human PBMC’s were differentiated to MDMs and treated with different concentrations of 2C-H. Further, cells were stimulated with 100ng/ml LPS, incubated for 16 hrs and cytokines assessed. Freshly isolated human PBMC’s were differentiated using human GM-CSF to macrophages. MDMs were treated with 100, 10, 1 and 0.1 μM of 2C-H and incubated for 1hr to allow cell penetration. Cells were stimulated with 100ng/ml LPS and incubated for 16 hours. Cell supernatant were collected to assess the cytokine levels. The results are shown in Figures 5 to 10. In Figures 5 to 10 the p values are as follows: ****p<0.0001 ***p<0.001 **p<0.01 *p<0.05 In Figures 5 to 10 negative and positive controls are as described herein. A 51% and 41% reduction respectively in IL-1Į and IL-1ǃ levels at 100ǋM of 2C-H treatment was observed. There was also significant reduction in levels of IL-6 (16%), TNF- Į (20%), IL-10 (22%) and IL-18 (17%) after treatment with 2C-H. 2C-H was thus found to have a significant anti-inflammatory effect in all cytokines tested but IL-6.

References 1. WO 2020/210823 A1 2. WO 2020/181194 A1 3. ACS Pharmacol. Transl. Sci. 2021, 4, pp.488-502. 4. WO 2007/044752 A2 5. J. Med. Chem. 1981, 24, pp. 1432-1437. 6. US 2010/001628 A1 7. British Journal of Pharmacology (2007) 152, 1121–1130 (DOI: 10.1038/sj.bjp.0707473)

Claims

Claims 1. A compound of Formula I: or a pharmaceu alt thereof, for use in the tr

eatment and/or prevention of a skin disorder.

2. A pharmaceutical composition comprising a compound of Formula I as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent for use in the treatment and/or prevention of a skin disorder.

3. The pharmaceutical composition for use according to claim 2, which is free from monoamine oxidase inhibitors.

4. The pharmaceutical composition for use according to claim 2 or 3, wherein said pharmaceutical composition is a topical pharmaceutical composition.

5. The pharmaceutical composition for use according to any one of claims 2-4, wherein the pharmaceutical composition is provided as a solution, emulsion, aerosol, spray, foam, lotion, cream, ointment, gel, paste or eye drops.

6. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to claim 1, or the pharmaceutical composition for use according to claim 2-5, wherein the skin disorder is an inflammatory skin disorder.

7. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to claim 1 or 6, or the pharmaceutical composition for use according to claims 2-6, wherein the skin disorder does not comprise psoriasis.

8. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to claim 1, 6 or 7, or the pharmaceutical composition for use according to any one of claims 2-7, wherein the skin disorder is rosacea.

9. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 or 6-8, or the pharmaceutical composition for use according to any one of claims 2-8, wherein the rosacea is one or more of the following types of rosacea: erythematotelangiectactic rosacea, papulopustular rosacea, phymateous rosacea, ocular rosacea.

10. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 or 6-9, or the pharmaceutical composition for use according to any one of claims 2-9, wherein the rosacea is erythematotelangiectactic rosacea and/or papulopustular rosacea.

11. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1, 6 or 7, or the pharmaceutical composition for use according to any one of claims 2-7, wherein the skin disorder is atopic dermatitis.

12. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1, 6 or 7, or the pharmaceutical composition for use according to any one of claims 2-7, wherein the skin disorder is perioral dermatitis.

13. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 or 6-12, or the pharmaceutical composition for use according to any one of claims 2-12, wherein the compound of Formula I or the pharmaceutical composition is administered to provide the compound of Formula I in a dosage from 0.01 mg/cm² to 10 mg/cm².

14. The compound of Formula I, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 or 6-13, or the pharmaceutical composition for use according to any one of claims 2-13, wherein the pharmaceutical composition is administered daily such as once daily.

15. Use of a compound of Formula I or a pharmaceu lt thereof, for the manufac

ture of a medicament for use in the treatment and/or prevention of a skin disorder.

16. Use of a pharmaceutical composition comprising a compound of Formula I as defined in claim 15, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent for the manufacture of a medicament for use in the treatment and/or prevention of a skin disorder.

17. The use according to claim 16, wherein the pharmaceutical composition is free from monoamine oxidase inhibitors.

18. The use according to claim 16 or 17, wherein the pharmaceutical composition is a topical pharmaceutical composition.

19. The use according to any one of claims 16-18, wherein the pharmaceutical composition is provided as a solution, emulsion, aerosol, spray, foam, lotion, cream, ointment, gel, paste or eye drops.

20. The use according to any one of claims 15-19, wherein the skin disorder is an inflammatory skin disorder.

21. The use according to any one of claims 15-20, wherein the skin disorder does not comprise psoriasis.

22. The use according to any one of claims 15-21, wherein the skin disorder is rosacea.

23. The use according to claim 22, wherein the rosacea is one or more of the following types of rosacea : erythematotelangiectactic rosacea, papulopustular rosacea, phymateous rosacea, ocular rosacea.

24. The use according to claim 22 or 23, wherein the rosacea is erythematotelangiectactic rosacea and/or papulopustular rosacea.

25. The use according to any one of claims 15-21, wherein the skin disorder is atopic dermatitis.

26. The use according to any one of claims 15-21, wherein the skin disorder is perioral dermatitis.

27. The use according to 15-26, wherein the compound of Formula I or the pharmaceutical composition is administered to provide the compound of Formula I in a dosage from 0.01 mg/cm² to 10 mg/cm².

28. The use according to 15-27, wherein the pharmaceutical composition is administered daily such as once daily.

29. A method for the treatment and/or prevention of a skin disorder, said method comprising administering to a mammal, such as a human or animal, in need thereof an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof.

30. A method for the treatment and/or prevention of a skin disorder, said method comprising administering to a mammal, such as a human or animal, in need thereof an effective amount of a pharmaceutical composition comprising a compound of Formula I as defined in claim 29, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable excipient, carrier and/or diluent.

31. The method according to claim 30, wherein the pharmaceutical composition is free from monoamine oxidase inhibitors.

32. The method according to claim 30 or 31, wherein the pharmaceutical composition is a topical pharmaceutical composition.

33. The method according to any one of claims 30-32, wherein the pharmaceutical composition is provided as a solution, emulsion, aerosol, spray, foam, lotion, cream, ointment, gel, paste or eye drops.

34. The method according to any one of claims 29-33, wherein the skin disorder is an inflammatory skin disorder.

35. The method according to 29-33, wherein the skin disorder does not comprise psoriasis.

36. The method according to 29-33, herein the skin disorder is rosacea.

37. The method according to 36, wherein the rosacea is one or more of the following types of rosacea: erythematotelangiectactic rosacea, papulopustular rosacea, phymateous rosacea, ocular rosacea.

38. The method according to 36 or 37, wherein the rosacea is erythematotelangiectactic rosacea and/or papulopustular rosacea.

39. The method according to 29-35, wherein the skin disorder is atopic dermatitis.

40. The method according to 29-35, wherein the skin disorder is perioral dermatitis.

41. The method according to 29-40, wherein the compound of Formula I or the pharmaceutical composition is administered to provide the compound of Formula I in a dosage from 0.01 mg/cm² to 10 mg/cm².

42. The method according to 29-41, wherein the pharmaceutical composition is administered daily such as once daily.

43. A solution, emulsion, aerosol, spray, foam, lotion, cream, ointment, gel, paste, eye drops, eye ointment comprising the pharmaceutical composition as defined in any one of claims 2-5, 16-19 or 31-33.

44. An article selected from the group consisting of a pad, a wipe and a patch, said article comprising the pharmaceutical composition as defined in any one of claims 2-5, 16-19 or 31-33.

45. The article according to claim 44, wherein said article is a wet wipe or a dermal patch. ^